Clinical Trial

Carbon Dioxide Administration and Brain Waste Clearance

Study acronym: COPETBI
Recruiting
View on ClinicalTrials.gov →
Summary
The current study tests whether different exposures to carbon dioxide (CO2) can safely result in the increased movement of proteins from the brain into the blood. The investigators believe that this would be a proxy for the brain clearing waste products more effectively. The current study will use a counter-balanced design, in which individuals with and without a history of traumatic brain injury (TBI) will receive different levels of CO2 (targeted changes of approximately 5 or 10 mmHG in end-tidal CO2) approximately one week apart. The counter-balanced design means that each participant receives a single dose of CO2 at each visit, and different doses of CO2 at each visit. The order in which participants receive the dose is randomized, and the participant will not be informed of the dose.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-15.
Trial Details
NCT Number NCT07357090
Lead Sponsor Andrew Mayer
Conditions Traumatic Brain Injury, Aging Disorder, Magnetic Resonance Imaging (MRI)
Enrollment 200 participants
Start Date 2026-04
Primary Completion 2031-01 (estimated)
Study Completion 2032-02 (estimated)
Updated on ClinicalTrials.gov 2026-02-23